Major Estimate Revision • Jun 26
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr169.0m to kr141.3m. Forecast losses increased from -kr0.405 to -kr0.465 per share. Biotechs industry in Sweden expected to see average net income growth of 14% next year. Consensus price target of kr2.50 unchanged from last update. Share price was steady at kr1.65 over the past week. Tillkännagivande • Jun 17
Oncopeptides AB (Publ) Announces Enrollment of First Patient in Oncopeptides' Glioblastoma Study Oncopeptides AB (publ) announced that the first patient has been enrolled in the clinical "Window-of-Opportunity" (WoO) study evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma. The WoO study, named OP-701 (INSULA), represents the first clinical evaluation of a PDC in glioblastoma, marking a major strategic milestone as Oncopeptides expands its core technology platform beyond multiple myeloma. The focused trial will enroll approximately 10 patients to provide initial human proof-of-concept to assess that the company's technology successfully penetrates the human blood-brain barrier (BBB) in glioblastoma patients and have cytotoxic (cell killing) activity in tumor cells. The BBB remains the primary clinical obstacle and causes most traditional oncological drugs to fail in this disease. By utilizing an approved drug from Oncopeptides' platform as a "clinical probe," the study employs an innovative and highly efficient design to capture drug activity directly within the tumor tissue from patients scheduled for surgery for recurrent disease. This approach aims to validate the underlying biological mechanism in a rapid, cost-efficient manner before advancing a PDC asset into formal dose-finding and potential further clinical trials. Glioblastoma is the most aggressive and devastating form of brain cancer, characterized by rapid tumor growth, invariable relapse, and a total lack of curative options, with a median survival rate of just 12–15 months. The global glioblastoma market represents a profound unmet medical need and is estimated to be worth more than 8 billion USD by 2035. Oncopeptides' PDC molecules are believed to be uniquely equipped to pass the blood-brain barrier due to their small size and lipophilicity, entering the target cancer cells freely to deliver their cytotoxic payload directly where it is needed. The trial is conducted at Oslo University Hospital in Norway. Tillkännagivande • May 22
Oncopeptides AB Announces Publication of Phase 2 Bridge Study Results for Pepaxti in Relapsed Refractory Multiple Myeloma Patients with Renal Impairment Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, announced the publication of the results from the Phase 2 BRIDGE (OP-107) clinical study in the peer-reviewed journal Clinical Lymphoma, Myeloma and Leukemia. The prospective, open-label study evaluated the pharmacokinetics (PK), safety, and efficacy of Pepaxti (melflufen) plus dexamethasone in relapsed, refractory multiple myeloma (RRMM) patients with moderate-to-severe renal impairment (RI). Patients with renal insufficiency represent roughly half of all myeloma diagnoses and typically suffer from poorer long-term outcomes and limited clinical options. The final analyses demonstrate that while systemic exposure to the active metabolite melphalan varies based on baseline kidney function, a reduced melflufen starting dose of 30 mg in patients with moderate renal impairment delivers a consistent safety profile, treatment responses, and survival measures aligned with prior trials conducted in less selected populations. Furthermore, exploratory data gathered across the treatment cycles showed that renal function remained stable or slightly improved during therapy, suggesting that Pepaxti does not adversely impact the kidneys at the studied doses. Validated dose optimization: The PK data directly validate the clinical use and efficacy of a 30 mg Pepaxti starting dose for patients with moderate renal impairment (eGFR =30 to <45 mL/min/1.73 m²). Sustained efficacy in fragile populations: Patients with moderate renal impairment achieved an Overall Response Rate (ORR) of 47.6% in Cohort 1a (40 mg starting dose) and 70.0% in Cohort 1b (30 mg starting dose), with a median progression-free survival (PFS) of 8.6 months and 7.7 months, respectively. No new safety signals: Despite advanced renal impairment and high treatment exposure, the safety profile was well-characterized and manageable. The most frequently reported treatment-emergent adverse events were hematological (thrombocytopenia, anemia, and neutropenia), which is consistent with previous clinical trials. The full article, titled "BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function," is available online via Clinical Lymphoma, Myeloma and Leukemia. Pepaxti (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. New Risk • May 19
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr221m Forecast net loss in 2 years: kr325k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr325k net loss in 2 years). Market cap is less than US$100m (kr676.7m market cap, or US$72.1m). Breakeven Date Change • May 19
Forecast to breakeven in 2028 The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 76% per year to 2027. The company is expected to make a profit of kr41.0m in 2028. Average annual earnings growth of 104% is required to achieve expected profit on schedule. Reported Earnings • May 15
First quarter 2026 earnings released First quarter 2026 results: Revenue: kr25.4m (up 91% from 1Q 2025). Net loss: kr32.2m (loss narrowed 47% from 1Q 2025). Revenue is forecast to grow 64% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 16
Oncopeptides AB (publ), Annual General Meeting, May 21, 2026 Oncopeptides AB (publ), Annual General Meeting, May 21, 2026, at 14:00 W. Europe Standard Time. Location: tandstickspalatset, vastra, tradgardsgatan 15, stockholm Sweden New Risk • Apr 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr559.7m market cap, or US$59.6m). New Risk • Mar 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-kr59m). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr19m net loss in 2 years). Market cap is less than US$100m (kr596.9m market cap, or US$64.2m). Tillkännagivande • Mar 18
Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million. Oncopeptides AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 200.389791 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 129,283,736
Price\Range: SEK 1.55
Transaction Features: Rights Offering Reported Earnings • Feb 20
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: kr1.10 loss per share (improved from kr1.71 loss in FY 2024). Revenue: kr71.1m (up 125% from FY 2024). Net loss: kr249.6m (loss narrowed 12% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 15%. Revenue is forecast to grow 61% p.a. on average during the next 2 years, compared to a 8.7% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. New Risk • Feb 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr45m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Market cap is less than US$100m (kr749.9m market cap, or US$82.8m). Breakeven Date Change • Feb 19
No longer forecast to breakeven The 2 analysts covering Oncopeptides no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr39.3m in 2027. New consensus forecast suggests the company will make a loss of kr1.00m in 2027. Major Estimate Revision • Jan 19
Consensus revenue estimates decrease by 15% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from kr83.4m to kr71.0m. EPS estimate unchanged from -kr0.96 per share at last update. Biotechs industry in Sweden expected to see average net income growth of 12% next year. Consensus price target down from kr5.25 to kr4.75. Share price fell 20% to kr3.30 over the past week. Tillkännagivande • Jan 17
Oncopeptides AB (Publ) Provides Sales Guidance for the Fourth Quarter and Full Year 2025 Oncopeptides AB (publ) provided sales guidance for the fourth quarter and full year 2025. For the quarter company expects net sales for the second quarter to amount to SEK 18.6 million an increase of 88% versus Fourth Quarter 2024.
For the full year, the company expects net sales to amount to 71.2 million SEK, an increase of 125% versus 2024. New Risk • Jan 16
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr268m Forecast net loss in 2 years: kr4.9m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr228m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr4.9m net loss in 2 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (27% increase in shares outstanding). Tillkännagivande • Jan 16
Oncopeptides AB (publ) to Report Fiscal Year 2025 Results on Feb 19, 2026 Oncopeptides AB (publ) announced that they will report fiscal year 2025 results on Feb 19, 2026 Major Estimate Revision • Nov 12
Consensus revenue estimates decrease by 37% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from kr131.5m to kr83.4m. EPS estimate unchanged from -kr0.97 per share at last update. Biotechs industry in Sweden expected to see average net income growth of 22% next year. Consensus price target of kr5.50 unchanged from last update. Share price was steady at kr5.10 over the past week. Reported Earnings • Nov 06
Third quarter 2025 earnings released: kr0.27 loss per share (vs kr0.29 loss in 3Q 2024) Third quarter 2025 results: kr0.27 loss per share. Revenue: kr20.2m (up 138% from 3Q 2024). Net loss: kr60.9m (loss widened 1.1% from 3Q 2024). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. New Risk • Oct 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 27% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-kr67m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr35m net loss in 2 years). Shareholders have been diluted in the past year (27% increase in shares outstanding). Tillkännagivande • Sep 01
Oncopeptides AB (publ) Announces the Publication of Two Real-World Evidence (RWE) Abstracts on Pepaxti At the International Myeloma Society Annual Meeting Oncopeptides AB (publ) announced the publication of two real-world evidence (RWE) abstracts on Pepaxti at the International Myeloma Society (IMS) Annual Meeting, September 17-20 in Toronto, Canada. As previously communicated, the data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The Italian study reports an overall response rate (ORR) of 47% in a heavily pretreated patient population with relapsed or refractory multiple myeloma, confirming the efficacy previously demonstrated in the HORIZON trial with a similar safety profile. Importantly, the study demonstrated efficacy in patients treated with novel immunotherapies, underscoring the robust effectiveness of Pepaxti in daily clinical practice. The Spanish study confirms the efficacy of Pepaxti in an even more heavily pretreated patient population where the majority of patients had been exposed to either anti-BCMA or anti-GPRC5D immunotherapy, generating data highly relevant to clinicians seeking guidance for treatment decisions. Both studies confirm Pepaxti's favorable tolerability profile in real-world settings - a key consideration in multiple myeloma where safety challenges are common. Recent Insider Transactions • Sep 01
Chief Executive Officer recently bought kr250k worth of stock On the 26th of August, Sofia Heigis bought around 57k shares on-market at roughly kr4.40 per share. This transaction amounted to 65% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sofia's only on-market trade for the last 12 months. Breakeven Date Change • Aug 25
Forecast to breakeven in 2027 The 2 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% per year to 2026. The company is expected to make a profit of kr13.0m in 2027. Average annual earnings growth of 79% is required to achieve expected profit on schedule. Reported Earnings • Aug 22
Second quarter 2025 earnings released: kr0.30 loss per share (vs kr0.48 loss in 2Q 2024) Second quarter 2025 results: kr0.30 loss per share (improved from kr0.48 loss in 2Q 2024). Revenue: kr19.2m (up 135% from 2Q 2024). Net loss: kr62.8m (loss narrowed 14% from 2Q 2024). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 22
Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million. Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 150.232109 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 46,947,534
Price\Range: SEK 3.2
Transaction Features: Rights Offering Buy Or Sell Opportunity • Aug 11
Now 21% undervalued Over the last 90 days, the stock has risen 139% to kr4.68. The fair value is estimated to be kr5.94, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.9% over the last 3 years. Earnings per share has grown by 86%. Revenue is forecast to grow by 569% in 2 years. Earnings are forecast to grow by 73% in the next 2 years. Tillkännagivande • Jul 23
Oncopeptides AB (publ) Announces Acceptance of Spanish and Italian Real-World Data at IMS Annual Meeting Oncopeptides AB (publ) announced that two real-world evidence (RWE) posters have been accepted for presentation at the upcoming International Myeloma Society (IMS) Annual Meeting, taking place in Toronto, Canada on September 17-20. The data were generated through treatment outcomes in real world settings from centers in Valencia, Spain and Bologna, Italy and underscore the growing interest in real-world clinical use of Pepaxti. The accepted posters focus on real-world outcomes in heavily pretreated patients with relapsed or refractory multiple myeloma. While specific results will be shared at the congress, the inclusion of these patient cases reflects the increasing importance of RWE to guide treatment decisions in clinical practice. For a medicine with limited awareness and use to date, real-world data play a key role in building physician confidence and informing market access. The inclusion of these two posters at IMS follows a growing body of independent research that reflects clinical experiences across Europe. New Risk • Jul 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Negative equity (-kr5.8m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr262m). Currently unprofitable and not forecast to become profitable over next 2 years (kr75m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Revenue is less than US$5m (kr40m revenue, or US$4.2m). Market cap is less than US$100m (kr501.2m market cap, or US$52.6m). Tillkännagivande • May 22
Oncopeptides AB (publ) Approves Election of Christine Rankin as Board Member The Annual General Meeting in Oncopeptides AB (publ) was held on 22 May 2025, approved election of Christine Rankin as board members. Major Estimate Revision • May 22
Consensus revenue estimates increase by 18% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from kr95.4m to kr112.4m. EPS estimate unchanged from -kr0.70 at last update. Biotechs industry in Sweden expected to see average net income growth of 25% next year. Consensus price target up from kr2.50 to kr2.73. Share price was steady at kr1.97 over the past week. Breakeven Date Change • May 21
Forecast to breakeven in 2027 The 3 analysts covering Oncopeptides expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 41% per year to 2026. The company is expected to make a profit of kr2.59m in 2027. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Reported Earnings • May 15
First quarter 2025 earnings released: kr0.29 loss per share (vs kr0.72 loss in 1Q 2024) First quarter 2025 results: kr0.29 loss per share (improved from kr0.72 loss in 1Q 2024). Revenue: kr13.3m (up 162% from 1Q 2024). Net loss: kr60.7m (loss narrowed 10% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. Tillkännagivande • May 06
Oncopeptides AB's Ordinary Shares to be Deleted from OTC Equity Oncopeptides AB (publ) Ordinary Shares will be deleted from OTC Equity effective May 06, 2025, due to inactive security. Tillkännagivande • Apr 17
Oncopeptides AB (publ), Annual General Meeting, May 22, 2025 Oncopeptides AB (publ), Annual General Meeting, May 22, 2025, at 10:00 W. Europe Standard Time. Location: at tandstickspalatset, vastra tradgardsgatan 15, stockholm Sweden Tillkännagivande • Apr 16
Oncopeptides AB (publ) Announces the Publication of New Real-World Data That Further Support the Effectiveness and Tolerability of Melflufen, Refractory Multiple Myeloma Oncopeptides AB (publ) announced the publication of new real-world data that further support the effectiveness and tolerability of melflufen, branded in Europe as Pepaxti, in patients with relapsed, refractory multiple myeloma (RRMM). The data were presented in an abstract from the University of Catania, Italy. It highlights treatment outcomes in a single-center real-world setting. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Notably, several patients presented with high-risk features, including extramedullary disease. Despite this, treatment with Pepaxti in combination with dexamethasone showed an overall response rate (ORR) of 37.5%, with partial responses seen even among patients with advanced disease manifestations. The data underline Pepaxti's role as a viable treatment option for patients with advanced RRMM for patients who have received at least three prior lines of therapy and whose disease has progressed on or after the last therapy. Price Target Changed • Mar 05
Price target decreased by 8.5% to kr2.50 Down from kr2.73, the current price target is an average from 3 analysts. New target price is 64% above last closing price of kr1.52. Stock is down 76% over the past year. The company is forecast to post a net loss per share of kr0.42 next year compared to a net loss per share of kr1.71 last year. Tillkännagivande • Mar 03
Oncopeptides AB (publ) to Report Q1, 2025 Results on May 15, 2025 Oncopeptides AB (publ) announced that they will report Q1, 2025 results on May 15, 2025 Reported Earnings • Mar 02
Full year 2024 earnings released: kr1.71 loss per share (vs kr2.76 loss in FY 2023) Full year 2024 results: kr1.71 loss per share. Revenue: kr31.6m (down 10% from FY 2023). Net loss: kr284.6m (loss widened 14% from FY 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden. Tillkännagivande • Feb 20
Oncopeptides AB (publ) to Report Q4, 2024 Results on Feb 27, 2025 Oncopeptides AB (publ) announced that they will report Q4, 2024 results at 8:00 AM, Central European Standard Time on Feb 27, 2025 Tillkännagivande • Feb 06
Jarl Ulf Jungnelius Resigns from Oncopeptides AB (publ) Board of Directors Oncopeptides AB (publ) announced that Jarl Ulf Jungnelius has informed the Board of Directors of his decision to step down from the Bord of Directors of Oncopeptides in which he has served since 2011. This due to personal reasons related to a change of domicile from Sweden. Tillkännagivande • Jan 27
Oncopeptides' Pepaxti Formally Approves for Full Reimbursement in Italy Oncopeptides AB (publ) announced that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal ("IOJ", It.: Gazetta Ufficiale). This marks the final regulatory step for the drug's upcoming commercialization in Italy, confirming Oncopeptides' expectation of first sales during first half, 2025. With the IOJ publication, Oncopeptides can now initiate the regional access process to bring Pepaxti to patients. The company's goal is to make the treatment available to eligible Italian patients with relapsed and refractory multiple myeloma over the coming months. Italy reports an annual incidence of approximately 6,000 new cases of multiple myeloma, and with about 1,800 patients falling within Pepaxti's target population. 79 patients across 10 Italian hospitals during the clinical development of Pepaxti and 86 treated patients in the Early Access Program (EAP) underscores the clinical experience in the country and high unmet need for the drug. The Early Access program have been closed following the reimbursement. As previously communicated, Oncopeptides is currently in the process of strengthening its presence in Italy by expanding its team and investing in initiatives to raise awareness about Pepaxti and its benefits. Major Estimate Revision • Nov 14
Consensus revenue estimates decrease by 19%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr50.6m to kr40.9m. EPS estimate increased from -kr2.38 to -kr1.58 per share. Biotechs industry in Sweden expected to see average net income growth of 29% next year. Consensus price target down from kr4.33 to kr3.00. Share price fell 5.4% to kr1.51 over the past week. Reported Earnings • Nov 08
Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.45 loss in 3Q 2023) Third quarter 2024 results: kr0.29 loss per share. Revenue: kr8.51m (up 203% from 3Q 2023). Net loss: kr60.2m (loss widened 49% from 3Q 2023). Revenue is forecast to grow 91% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. New Risk • Nov 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (127% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr134m net loss in 2 years). Share price has been volatile over the past 3 months (8.9% average weekly change). Revenue is less than US$5m (kr21m revenue, or US$2.0m). Market cap is less than US$100m (kr343.4m market cap, or US$32.1m). Major Estimate Revision • Sep 12
Consensus revenue estimates decrease by 34%, EPS upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from kr76.3m to kr50.6m. EPS estimate increased from -kr2.21 to -kr2.02 per share. Biotechs industry in Sweden expected to see average net income growth of 5.3% next year. Consensus price target down from kr5.77 to kr4.33. Share price was steady at kr2.07 over the past week. Price Target Changed • Sep 11
Price target decreased by 29% to kr4.33 Down from kr6.10, the current price target is an average from 3 analysts. New target price is 110% above last closing price of kr2.07. Stock is down 74% over the past year. The company is forecast to post a net loss per share of kr2.02 next year compared to a net loss per share of kr2.76 last year. Reported Earnings • Aug 19
Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023) Second quarter 2024 results: kr0.48 loss per share. Net loss: kr73.2m (loss widened 30% from 2Q 2023). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Major Estimate Revision • Aug 15
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr84.2m to kr74.6m. Forecast losses increased from -kr2.04 to -kr2.21 per share. Biotechs industry in Sweden expected to see average net income growth of 34% next year. Consensus price target down from kr6.10 to kr5.77. Share price fell 11% to kr2.12 over the past week. Tillkännagivande • Jul 04
An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million. An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million on July 2, 2024. Industrifonden Foundation has divested its entire stake in Oncopeptides.
An undisclosed buyer completed the acquisition of 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden on July 2, 2024. Major Estimate Revision • Jun 06
Consensus EPS estimates fall by 34%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from kr82.4m to kr84.2m. Forecast EPS reduced from -kr1.53 to -kr2.04 per share. Biotechs industry in Sweden expected to see average net income growth of 19% next year. Consensus price target of kr6.10 unchanged from last update. Share price rose 19% to kr3.44 over the past week. Reported Earnings • Jun 04
First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023) First quarter 2024 results: kr0.75 loss per share (improved from kr0.75 loss in 1Q 2023). Revenue: kr5.07m (up 351% from 1Q 2023). Net loss: kr67.7m (loss narrowed 4.7% from 1Q 2023). Revenue is forecast to grow 62% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Tillkännagivande • May 17
Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress Oncopeptides AB (publ) announced that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Cont Cont Cont Controversies in Multiple Myeloma (COMy), to be held on May 23-26. The study, published by a team from institutions across Europe, including the University of Wurzburg and the Institute for Molecular Medicine Finland, focuses on the effectiveness of melflufen and shows promising results for the drug when treating patients with a particularly challenging form of multiple myeloma. The study will be presented to congress attendees through an online oral presentation on May 26. The presentation will be given by Caroline Heckman, from the Institute for Molecular Medicine Finland. Multiple myeloma can be especially difficult to treat in patients who have specific genetic mutations or deletions, such as del(17p) and/or mutations in the TP53 gene. These genetic characteristics are associated with a poorer prognosis and shorter survival rates. The research findings indicate that melflufen is more effective than traditional alkylating agents causing DNA damage and promoting the death of cancer cells lacking a functional so-called p53 protein, which is a common issue in high-risk multiple myeloma cases. The study also highlighted significant changes in gene expression that enhance the drug's impact on cancer cells. Furthermore, patients with the del(17p) genetic abnormality treated with melflufen and dexamethasone showed a longer progression-free survival and higher overall response rate compared to those treated with pomalidomide and dexamethasone in the OP-103 OCEAN trial. New Risk • May 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 133% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Shareholders have been substantially diluted in the past year (133% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr66m net loss in 3 years). Revenue is less than US$5m (kr35m revenue, or US$3.2m). Market cap is less than US$100m (kr637.2m market cap, or US$58.4m). Price Target Changed • Apr 25
Price target decreased by 7.2% to kr6.40 Down from kr6.90, the current price target is an average from 2 analysts. New target price is 99% above last closing price of kr3.22. Stock is down 71% over the past year. The company is forecast to post a net loss per share of kr1.53 next year compared to a net loss per share of kr2.76 last year. Major Estimate Revision • Apr 18
Consensus EPS estimates fall by 38% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -kr1.80 to -kr2.48 per share. Revenue forecast of kr105.1m unchanged since last update. Biotechs industry in Sweden expected to see average net income growth of 10% next year. Consensus price target of kr6.80 unchanged from last update. Share price fell 11% to kr4.47 over the past week. Tillkännagivande • Apr 05
Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024 Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million). Tillkännagivande • Mar 13
Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million. Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Transaction Features: Rights Offering New Risk • Feb 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr279m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr279m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr50m net loss in 3 years). Revenue is less than US$5m (kr35m revenue, or US$3.4m). Market cap is less than US$100m (kr487.2m market cap, or US$47.1m). Tillkännagivande • Feb 24
Oncopeptides AB (publ), Annual General Meeting, May 22, 2024 Oncopeptides AB (publ), Annual General Meeting, May 22, 2024. Tillkännagivande • Dec 16
Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines Oncopeptides announced that the European Commission has decided to formally approve the company’s application to the European Medicines Agency (EMA) for an extended indication for Pepaxti into earlier lines. The previously communicated decision by Oncopeptides to opt out of the process to extend the indication remains. Oncopeptides has submitted an application to adjust the indication of Pepaxti to the originally approved indication, a process that is expected to be finalized in early 2024. During this time, Oncopeptides will work together with the European Commission, EMA as well as local stakeholders to ensure an efficient removal process for the extended indication. Tillkännagivande • Nov 18
Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024 Oncopeptides AB (publ) announced that they will report Q3, 2024 results on Nov 07, 2024 Tillkännagivande • Nov 15
Oncopeptides Selects to Present Additional Data from Ocean Study Oncopeptides AB (publ) announced that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12. ASH is the world's professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases. The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies. Tillkännagivande • Oct 27
Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024 Oncopeptides AB (publ) announced that they will report Q2, 2024 results at 8:00 AM, Central European Standard Time on Aug 14, 2024 Tillkännagivande • Oct 21
Oncopeptides AB (publ) Announces the Nomination Committee Oncopeptides AB (publ) announces that the composition of the Nomination Committee has been established. According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2024 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2023 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors. The Nomination Committee in respect of the annual general meeting 2024 consists of the following persons who together represent approximately 29 percent of the number of shares and votes in the company based on the shareholder information at end of September 2023. Staffan Lindstrand, appointed by HealthCap VI L.P., Patrik Sobocki, appointed by Stiftelsen Industrifonden, Caroline Mebius, appointed by Handelsbanken funds, and Per Wold-Olsen, the Chairman of the Board. Tillkännagivande • Oct 12
Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024 Oncopeptides AB (publ) announced that they will report Q1, 2024 results on May 03, 2024 Tillkännagivande • Oct 02
Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024 Oncopeptides AB (publ) announced that they will report fiscal year 2023 final results on Apr 22, 2024 Tillkännagivande • Sep 21
Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024 Oncopeptides AB (publ) announced that they will report fiscal year 2023 results on Feb 27, 2024 Tillkännagivande • Sep 15
Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results Oncopeptides AB (publ) announced that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has, following their scientific assessment, adopted a positive opinion on Oncopeptides' application for earlier lines of treatment for patients with relapsed, refractory multiple myeloma (RRMM). The opinion from the CHMP will now be sent to the European Commission for a final decision. Based on findings from its OCEAN trial, Oncopeptides submitted, on 28 Nov. 2022, an application to extend the therapeutic indication of Pepaxti to the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy. With their opinion, CHMP recommends that the use of Pepaxti could be expanded to earlier lines of treatment and also peripheral administration, meaning delivery of treatment through peripheral rather than central veins, a less invasive way of administration. Oncopeptides will as a next step assess the current market dynamics of the rapidly evolving multiple myeloma landscape, including the competition in different lines of treatment and the effect that extending Pepaxti into earlier lines of treatment would have on Oncopeptides's ability to receive a reimbursed price that reflects its innovation. Major Estimate Revision • Aug 17
Consensus revenue estimates increase by 47% The consensus outlook for revenues in fiscal year 2023 has improved. 2023 revenue forecast increased from kr25.6m to kr37.6m. Forecast losses expected to reduce from -kr2.94 to -kr2.81 per share. Biotechs industry in Sweden expected to see average net income growth of 4.3% next year. Consensus price target down from kr14.50 to kr11.25. Share price fell 12% to kr6.99 over the past week. 
